LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference
LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference
LENZ Therapeutics (Nasdaq: LENZ) will report first quarter 2026 financial results and corporate highlights via a live webcast on May 11, 2026 at 4:30 p.m. EDT. The company commercializes VIZZ® (aceclidine ophthalmologic solution) 1.44%, indicated for presbyopia in adults.
Management will also hold one-on-one meetings at the Bank of America Global Healthcare Conference on May 13–14, 2026 in Las Vegas. A webcast replay will be available on the company website for 30 days.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – LENZ
+4.50%
10 alerts
+4.50%Session close to close
+3.0%Peak in 8 min
$298.49MMarket Cap
0.3xRel. Volume
In the May 4 session, LENZ gained 4.50%, reflecting a moderate positive market reaction.
Argus tracked a peak move of +3.0% during that session.
Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.
This announcement sets the timing for LENZ’s Q1 2026 results and highlights continued investor outre...
Analysis
This announcement sets the timing for LENZ’s Q1 2026 results and highlights continued investor outreach via the Bank of America Global Healthcare Conference. It follows a year in which LENZ generated $19.1M in 2025 revenue, including $1.6M from VIZZ product sales, while posting a $82.1M net loss and $91.1M in SG&A as commercialization scaled. Investors may focus on updated prescription trends, cash usage versus the $292.3M year-end balance, and progress on ex‑U.S. regulatory and partnering initiatives.
Key Figures
Q4 2025 product revenue:$1.6 millionYear 2025 revenue:$19.1 millionEx‑U.S. license and milestones:$17.5 million+5 more
8 metrics
Q4 2025 product revenue$1.6 millionFourth quarter and full year 2025 results
Year 2025 revenue$19.1 millionTotal 2025 revenue from product sales and ex‑U.S. licenses
Ex‑U.S. license and milestones$17.5 millionPortion of 2025 revenue from ex‑U.S. license payments
2025 net loss$82.1 millionFull year 2025 net loss, $2.85 per share
2025 SG&A expenses$91.1 millionSelling, general and administrative for 2025 commercial build-out
2025 R&D expenses$18.7 millionResearch and development spending in 2025
Cash and securities$292.3 millionCash, cash equivalents and marketable securities at Dec 31, 2025
Presbyopia market opportunity>$3 billionEstimated U.S. self-pay market opportunity for VIZZ
Planned presentations and 1x1 meetings at early March conferences.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent fundamentally positive updates, including regulatory submissions and 2025 results, were often followed by negative price reactions, while neutral conference and earnings-date announcements saw modest gains.
Recent Company History
Over the past few months, LENZ has transitioned deeper into commercialization of VIZZ®. On Mar 24, 2026, it reported Q4 and full-year 2025 results with $1.6M in product revenue and $292.3M in cash, yet shares fell 17.91%. Multiple ex‑U.S. regulatory submissions for VIZZ, including to the EMA on Mar 10, 2026 and UK MHRA on Apr 20, 2026, also saw small negative moves. In contrast, purely informational items like conference appearances and the prior earnings-date announcement produced modest gains, framing today’s scheduling of Q1 results and an investor conference as part of a continuing outreach cadence.
Key Terms
marketing authorization application, european medicines agency, schedule 13g, schedule 13g/a, +4 more
8 terms
marketing authorization applicationregulatory
"submitted a Marketing Authorization Application to the European Medicines Agency"
A marketing authorization application is a formal request submitted to a government regulator asking permission to sell a prescription medicine or medical product in a country or region. Think of it like asking for a business license after showing evidence the product is safe and works; investors care because approval determines whether the product can generate sales, how soon revenue starts, and how much regulatory risk and uncertainty remains.
european medicines agencyregulatory
"submitted a Marketing Authorization Application to the European Medicines Agency for VIZZ"
The European Medicines Agency is the central drug regulator that evaluates and authorizes medicines for use across the European Union and related countries, similar to a referee or safety inspector who checks that a medicine is safe and effective before it can be sold. Its decisions matter to investors because approvals, rejections, or safety warnings directly affect a drug maker’s ability to sell products, generate revenue, and face legal or reputational risks, which in turn influence stock value.
schedule 13gregulatory
"BlackRock, Inc. files a Schedule 13G reporting beneficial ownership"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
schedule 13g/aregulatory
"In this Schedule 13G/A amendment, Ridgeback Capital Investments L.P."
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
form 4regulatory
"title": "[Form 4] LENZ Therapeutics, Inc. Insider Trading Activity""
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
"title": "[10-K] LENZ Therapeutics, Inc. Files Annual Report""
A 10-K is a comprehensive annual report a public company files with the U.S. Securities and Exchange Commission that summarizes its business, financial results, risks, legal issues, and management discussion. Investors use it like a company’s detailed yearly report card and instruction manual — it helps reveal how the company makes money, where it might face trouble, and the underlying numbers that support valuation and investment decisions.
"title": "[8-K] LENZ Therapeutics, Inc. Reports Material Event""
An 8-K is a public report companies must file with the U.S. Securities and Exchange Commission to disclose major events or changes that shareholders should know about, such as leadership changes, mergers, financial surprises, or legal developments. It matters to investors because it acts like a breaking-news alert for a company’s health and prospects—providing timely facts that can affect stock value and investment decisions.
"plus U.S. NCE exclusivity to <date>July 2030</date>"
NCE exclusivity (New Chemical Entity exclusivity) is a fixed period of regulatory protection granted to a newly approved drug whose active ingredient has never before been approved. It prevents competitors from obtaining approval for generic versions that rely on the original drug’s approval data, acting like a temporary market-only window that reduces immediate competition. For investors, this protection can help preserve a drug’s sales and cash flow during the exclusivity period, making projected revenues more predictable.
SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Monday, May 11, 2026, at 4:30 p.m. EDT to report its first quarter 2026 financial results and recent corporate highlights.
To participate in the conference call via telephone, dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) and enter code 1358554. The live webcast can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section. A replay of the webcast will be available on the Company’s website for 30 days following the event.
In addition, company management will host one-on-one meetings at the Bank of America Global Healthcare Conference on May 13–14, 2026, in Las Vegas, Nevada.
About LENZ Therapeutics LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. LENZ is commercializing VIZZ in the United States and continues to establish licensing partnerships internationally to provide access to VIZZ globally. LENZ is headquartered in San Diego, California. For more information, visit www.VIZZ.com and www.LENZ-tx.com.
Contacts: Dan Chevallard LENZ Therapeutics IR@LENZ-Tx.com
FAQ
When will LENZ report Q1 2026 financial results and how can I join the May 11, 2026 webcast?
LENZ will report Q1 2026 results on May 11, 2026 at 4:30 p.m. EDT. According to the company, join the live webcast on its investor website or dial the domestic phone line using access code 1358554 for the conference call.
What product does LENZ commercialize and what is its approved use by the FDA?
LENZ commercializes VIZZ (aceclidine 1.44%), the first FDA-approved aceclidine ophthalmic drop for presbyopia in adults. According to the company, VIZZ is indicated to treat presbyopia and is the firm’s primary commercial product.
Will LENZ provide a replay of the May 11, 2026 webcast and where can investors access it?
Yes. According to the company, a replay of the May 11, 2026 webcast will be available on the LENZ investor website for 30 days following the live event. Investors can access it in the Investors & Media section of the website.
Is LENZ attending any investor conferences in May 2026 and when are those meetings scheduled?
LENZ management will attend the Bank of America Global Healthcare Conference on May 13–14, 2026. According to the company, management will host one-on-one investor meetings in Las Vegas during those conference dates.
How do I join LENZ’s conference call by phone for the May 11, 2026 financial results?
Dial (800) 715-9871 (domestic) or (646) 307-1963 (international) and enter access code 1358554. According to the company, those numbers and the code provide telephone access to the May 11, 2026 conference call.
